Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K33/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210128730METHODS FOR TREATING TUMORS
US 06.05.2021
Int.Class A61K 41/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation
Appl.No 16628611 Applicant NH THERAGUIX Inventor François LUX

The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

2.20210128630PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF
US 06.05.2021
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
Appl.No 16639474 Applicant Children's Medical Center Corporation Inventor S. Alexander Mitsialis

Provided herein are isolated exosomes from mesenchymal stem cells (MSC). Such isolated exosomes are substantially CT free of contaminants and are therapeutically active in treating various diseases (e.g., lung diseases such as BPD). The isolated MSC exosomes are identified by one or more protein markers described herein. Methods of purifying such MSC exosomes are also provided.

3.20210128522TERPENE-ENRICHED CANNABINOID COMPOSITION FOR TREATMENT OF MALE SUBJECTS
US 06.05.2021
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No 17144171 Applicant BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. Inventor Noa RAZ

Provided is a method for treating conditions and/or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and/or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.

4.WO/2021/084869MANUFACTURING METHOD FOR MICROBUBBLE-CONTAINING ELECTROLYTE AND MANUFACTURING METHOD FOR MICROBUBBLE-CONTAINING SOLVENT FOR USE IN PREPARING MICROBUBBLE-CONTAINING ELECTROLYTE
WO 06.05.2021
Int.Class A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Appl.No PCT/JP2020/031887 Applicant AICHI MEDICAL UNIVERSITY Inventor HATAYAMA Naoyuki
Provided are: a manufacturing method for an electrolyte that can contain microbubbles at a high concentration by suppressing a reduction in microbubbles during filtering; and a manufacturing method for a microbubble-containing solvent that can be used to prepare the electrolyte. This manufacturing method for a microbubble-containing electrolyte includes a filtering process in which a microbubble-containing solvent is filtered using a filtering material, and a preparation step in which an electrolyte is prepared from the obtained filtrate, wherein the positive ion concentration in the microbubble-containing solvent is less than 20 mmol/L, and at least one of the following conditions (1), (2), and (3) is met. Condition (1): the density of microbubbles in the microbubble-containing solvent is at least 1 × 106 bubbles/mL. Condition (2): a solvent preparation step is included in which microbubbles are introduced into a solvent and a microbubble-containing solvent is prepared. Condition (3): the density of microbubbles in the electrolyte is at least 1 × 105 bubbles/mL.
5.WO/2021/087419NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE
WO 06.05.2021
Int.Class A61K 33/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
Appl.No PCT/US2020/058446 Applicant VERTELOVA, Regina Inventor VERTELOVA, Regina
The invention is directed to a composition of metal particles and methods of manufacturing and using the composition in the treatment of microbial infections and cancer. The particles can be nanoparticles having coupled thereto at least one of a surfactant, an antibiotic, and a drug. The particles of the invention achieve enhanced stability, enhanced cytotoxicity, and enhanced antimicrobial activity through novel combinations of metals, surfactants, antibiotics, and drugs.
6.20210128575PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
US 06.05.2021
Int.Class A61K 31/5415
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
5415ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
Appl.No 17145744 Applicant AXSOME THERAPEUTICS, INC. Inventor Herriot Tabuteau

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

7.20210128535Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof
US 06.05.2021
Int.Class A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Appl.No 16488884 Applicant IMPACT THERAPEUTICS, INC. Inventor Suixiong CAI

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I:

embedded image

or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A3, B1-B3, D1-D4 and R1-R2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

8.20210128545COMBINATION THERAPY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
US 06.05.2021
Int.Class A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Appl.No 17089359 Applicant Celgene Corporation Inventor Tonia Buchholz

Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.

9.WO/2021/083964NEW MEANS AND METHODS FOR THERAPY AND DIAGNOSIS OF DNA VIRUS INFECTIONS
WO 06.05.2021
Int.Class A61K 33/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
36Arsenic; Compounds thereof
Appl.No PCT/EP2020/080299 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor SCHREINER, Sabrina
The present invention relates to the field of DNA virus infection, in particular to therapy and diagnosis of a DNA virus infection in a subject. Specifically, the present invention relates to the use of arsenic trioxide (As2O3) for treating or preventing an adenovirus infection or hepatitis B virus (HBV) infection in a subject. Furthermore, the present invention relates to a method of detecting an adenovirus infection or HBV infection based on detecting SUMOylation of adenoviral E2A protein or HBV core (HBc) protein, respectively, in a patient sample.
10.WO/2021/084361USE OF EXFOLIATED BLACK PHOSPHORUS FOR THE TREATMENT OF PROSTATE CANCERS
WO 06.05.2021
Int.Class A61K 33/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
42Phosphorus; Compounds thereof
Appl.No PCT/IB2020/059686 Applicant MATERIAS S.R.L. Inventor RAUCCI, Maria Grazia
The present invention relates to exfoliated black phosphorus for use in the treatment of prostate cancer with or without irradiation by photothermal or photodynamic therapy.